Management of linear IgA disease

Dermatol Clin. 2011 Oct;29(4):629-30. doi: 10.1016/j.det.2011.06.014.

Abstract

Linear immunoglobulin A (IgA) disease is an acquired autoimmune blistering disease of the skin and mucous membranes that runs a chronic course over 3 to 6 years before remitting. It typically presents with papulovesicles and blisters configured in an arcuate pattern on an urticated base, with 2 peaks of onset. The first peak is in young prepubescent children, called chronic bullous disease of childhood, and the second peak affects patients older than 60 years of age. In this article, the management of linear IgA in adults is considered.

MeSH terms

  • Autoimmune Diseases / drug therapy*
  • Chronic Disease
  • Dermatologic Agents / therapeutic use
  • Humans
  • Immunoglobulin A / drug effects*
  • Skin Diseases, Vesiculobullous / drug therapy*
  • Sulfones / therapeutic use*
  • Treatment Outcome

Substances

  • Dermatologic Agents
  • Immunoglobulin A
  • Sulfones